ArticleThoracic cancer2020
New relationship of E2F1 and BNIP3 with caveolin-1 in lung cancer-associated fibroblasts.
Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Targeting caveolin-1: dual challenges in tumor immunity and drug therapy strategies.Cancer cell international · 2026Review
- Hidden forces: the impact of cancer-associated fibroblasts on non-small cell lung cancer development and therapy.Journal of translational medicine · 2025Review
- The crosstalk of caveolin-1 and autophagy in different diseases.Frontiers in immunology · 2025Review
- KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1.Human cell · 2022Article
- Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis.International journal of general medicine · 2022Article
- [Advancement of E2F1 in Common Tumors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
Corrections and comments
- Comment on
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, studies have found that E2F1, a downstream effector of caveolin-1 (Cav-1), participates in tumor cell metabolic reprogramming. E2F1 modulates mitochondrial fusion and mitophagy. Bioinformatic analysis has identified the E2F1-MFN2 axis as a regulator of mitophagy. Our data establish a new novel paradigm for regulation of the tumor cell metabolic reprogramming pathway by Cav-1 that is operationally linked and mutually dependent on the transcriptional activation of E2F1 and induces mitophagy with BNIP3 in cancer-associated fibroblasts (CAFs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.